Effects of Landiolol, an Ultra-Short-Acting .BETA.1-Selective Blocker, on Electrical Storm Refractory to Class III Antiarrhythmic Drugs

DOI Web Site PubMed 被引用文献23件 参考文献42件
  • Miwa Yosuke
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Ikeda Takanori
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Mera Hisaaki
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Miyakoshi Mutsumi
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Hoshida Kyoko
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Yanagisawa Ryoji
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Ishiguro Haruhisa
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Tsukada Takehiro
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Abe Atsuko
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Yusu Satoru
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Yoshino Hideaki
    Second Department of Internal Medicine, Kyorin University School of Medicine

この論文をさがす

説明

Background: Occasionally it is difficult to inhibit electrical storm (ES) with standard pharmacological treatment. In the present study the effect of landiolol, an ultra-short-acting β1-selective blocker, on ES refractory to class III antiarrhythmic drugs was evaluated. Methods and Results: The study group comprised 42 consecutive patients who developed ES for which intravenous class III antiarrhythmic drugs, such as amiodarone and nifekalant, were ineffective. Landiolol was administered intravenously with an initial dose of 2.5 μg · kg–1 · min–1, which was doubled if it was ineffective, up to a maximum dose of 80 μg · kg–1 · min–1. Landiolol inhibited ES in 33 patients (79%) at a mean dose of 7.5±12.2 μg · kg–1 · min–1. All patients in whom landiolol was ineffective died of arrhythmia. Of the 33 patients in whom landiolol was effective, 25 survived and were discharged (60% of all patients). Landiolol significantly decreased heart rate (P<0.0001), but did not affect blood pressure. Landiolol was not discontinued for adverse effects in any of the responders. Age, APACHE II score, and pH of arterial blood gas differed significantly between the responders and nonresponders. Conclusions: Landiolol is useful as a life-saving drug for class III antiarrhythmic drug-resistant ES. The main mechanism of ES refractory to class III antiarrhythmic drugs could be abnormal automaticity but not reentry. (Circ J 2010; 74: 856 - 863)<br>

収録刊行物

  • Circulation Journal

    Circulation Journal 74 (5), 856-863, 2010

    一般社団法人 日本循環器学会

被引用文献 (23)*注記

もっと見る

参考文献 (42)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ